Press Releases

Glioblastoma Multiforme Treatment Market to Reach US$ 10.2 Bn by 2030

Share This Article

The global Glioblastoma Multiforme Treatment market size is expected to reach USD 10.2 billion by 2030, registering a CAGR of 12.8% over the forecast period 2021 – 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38479

Growth Factors

 The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy. In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years. The growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios are among the factors anticipated to fuel the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period.

Report Highlights

Radiation therapy dominated the market with a revenue share of 47.6% in 2020 owing to the improved survival rates. Radiation therapy can be recommended as the first treatment or combined with chemotherapy and surgery. It is also effective and highly recommended for brain tumors in case of recurrence. The use of temozolomide along with radiotherapy makes the tumor more sensitive to radiation. This combination of therapy is more effective than radiation without temozolomide.

The others segment accounted for the largest revenue share of 76.4% in 2020. The other drugs segment includes drugs such as everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA). Corticosteroids are mainly prescribed to reduce the peritumoral vasogenic edema for symptomatic benefits. Dexamethasone is mainly prescribed due to its lack of mineralocorticoid activity.

North America accounted for the largest share of 53.6% in 2020. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility of quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth.

Key Players

  • Merck & Co., Inc.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Amgen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Arbor Pharmaceuticals, LLC
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics, Inc.
  • Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
Report Coverage Details
Market Size USD 10.2 Billion by 2030
Growth Rate CAGR of 12.8% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Treatment, Drug class, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Merck & Co., Inc.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Amgen, Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, LLC; Amneal Pharmaceuticals; Karyopharm Therapeutics, Inc.; Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

Market Segmentation

  • Treatment
    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • Targeted Therapy
    • Tumor Treating Field (TTF) Therapy
    • Immunotherapy
  • Drug Class
    • Temozolomide
    • Bevacizumab
    • Lomustine
    • Carmustine Wafers
    • Others
  • End-use
    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Singapore
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38479

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Glioblastoma Multiforme Treatment Market, By Treatment

7.1.  Glioblastoma Multiforme Treatment Market, by Treatment, 2021-2030

7.1.1.    Surgery

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Radiation Therapy

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Chemotherapy

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Targeted Therapy

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    Tumor Treating Field (TTF) Therapy

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    Immunotherapy

7.1.6.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Glioblastoma Multiforme Treatment Market, By Drug Class

8.1.  Glioblastoma Multiforme Treatment Market, by Drug Class, 2021-2030

8.1.1.    Temozolomide

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Bevacizumab

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Lomustine

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Carmustine Wafers

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Others

8.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Glioblastoma Multiforme Treatment Market, By End User

9.1.  Glioblastoma Multiforme Treatment Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Clinics

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Ambulatory Surgical Centers

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Glioblastoma Multiforme Treatment Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.1.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.2.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.3.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.4.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.5.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Merck & Co., Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Amgen, Inc.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              F. Hoffmann-La Roche Ltd.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Pfizer Inc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Amgen, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Teva Pharmaceutical Industries Ltd.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Sun Pharmaceutical Industries Ltd.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Arbor Pharmaceuticals, LLC

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Amneal Pharmaceuticals

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Karyopharm Therapeutics, Inc.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38479

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Related Articles

Back to top button